1 Loss of function, missense, and intronic variants in *NOTCH1* confer different risks for
2 left ventricular outflow tract obstructive heart defects in two European cohorts.

3

4

5 *NOTCH1* variants in congenital heart disease

6

7 Emmi Helle^{1,2,¶}, Aldo Córdova-Palomera^{3¶}, Tiina Ojala¹, Priyanka Saha³, Praneetha
8 Potiny³, Stefan Gustafsson⁴, Erik Ingelsson^{2,4}, Michael Bamshad^{5, 6, 7}, Deborah
9 Nickerson⁶, Jessica X. Chong⁵, University of Washington Center for Mendelian
10 Genomics, Euan Ashley², James R Priest^{2,3}.

11

12 ¹ Children's Hospital, University of Helsinki, Helsinki, Finland

13 ² Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA

14 ³ Department of Pediatrics, Division of Pediatric Cardiology Stanford University
15 School of Medicine, Stanford, CA

16 ⁴ Department of Medical Sciences, Molecular Epidemiology and Science for Life
17 Laboratory, Uppsala University, Uppsala, Sweden.

18 ⁵ Department of Pediatrics, University of Washington, Seattle, WA

19 ⁶ Department of Genome Sciences, University of Washington, Seattle, WA

20 ⁷ Division of Genetic Medicine, Seattle Children's Hospital, Seattle, WA

21

22 ¶ These authors contributed equally

23

24 Corresponding Author: James R Priest

25 E-mail: jpriest@stanford.edu (JRP)

26

Abstract

Loss of function variants in *NOTCH1* cause left ventricular outflow tract obstructive defects (LVOTO) in a small percentage of families. Clinical surveys report an increased prevalence of missense variants in *NOTCH1* in family members of individuals with LVOTO and other types of congenital heart disease (CHD). However, the risk conferred by rare variants in *NOTCH1* for LVOTO remains largely uncharacterized. In a cohort of 49 families affected by hypoplastic left heart syndrome, a severe form of LVOTO, we discovered predicted loss of function *NOTCH1* variants in 6% of individuals. Rare missense variants were found in an additional 16% of families. To make a quantitative estimate of the genetic risk posed by variants in *NOTCH1* for LVOTO, we studied associations of 400 coding and non-coding variants in *NOTCH1* in 271 adult cases and 333,571 controls from the UK Biobank. Two rare intronic variants in strong linkage disequilibrium displayed significant association with risk for LVOTO (g.chr9:139427582C>T, Odds Ratio 16.9, $p=3.12e-6$; g.chr9:139435649C>T, Odds Ratio 19.6, $p = 2.44e-6$) amongst European-ancestry British individuals. This result was replicated in an independent analysis of 51 cases and 68,901 controls of non-European and mixed ancestry. We conclude that carrying rare predicted loss of function variants or either of two intronic variants in *NOTCH1* confer significant risk for LVOTO. Our approach demonstrates the utility of population-based datasets in quantifying the specific risk of individual variants for disease related phenotypes.

52 **Author summary**

53

54 Congenital heart defects are the most common class of birth defect and are present
 55 in 1% of live births. Although CHD cases are often clustered in families, and thus the
 56 causal variant(s) are seemingly inherited, finding genetic variants causing these
 57 defects has been challenging. With the knowledge that variation in the *NOTCH1*
 58 gene previously has been associated with CHDs affecting the left side of the heart,
 59 our aim was to further investigate the role of different types of *NOTCH1* variants in
 60 left sided CHDs in two cohorts – a cohort of Finnish families with severe lesions
 61 affecting the left side of the heart , and the UK Biobank population including
 62 individuals with less severe left-sided lesions such as bicuspid aortic valve,
 63 congenital aortic stenosis, and coarctation of the aorta. We found a causal loss-of-
 64 function *NOTCH1* variant in 6% of the families in the Finnish cohort and in the UK
 65 Biobank cohort, we identified two rare variants in the non-coding region of *NOTCH1*,
 66 associated with severe left-sided CHDs. These findings support screening of
 67 *NOTCH1* loss-of-function variants in patients with severe left sided congenital heart
 68 defects and suggests that non-coding region variants in *NOTCH1* play a role in
 69 CHDs.

70

71

72 Introduction

73 Congenital heart defects (CHDs) are the most common congenital malformations
 74 and occur in 0.8-1% of live births [1]. Left ventricular outflow tract obstruction
 75 (LVOTO) is a subtype of CHD affecting one or more structures on the left side of the
 76 heart – left ventricle, aortic valve and thoracic aorta. At its most severe, LVOTO
 77 defects manifest as hypoplastic left heart syndrome (HLHS), in which the left
 78 ventricle is underdeveloped, and the systemic circulation depends the persistence of
 79 fetal circulatory physiology. Other common LVOTO defects include aortic coarctation
 80 (CoA), congenital aortic stenosis (AS), and bicuspid aortic valve (BAV) [1].

81
 82 The genetic basis of non-syndromic LVOTO defects is largely unknown. Non-
 83 syndromic LVOTO defects frequently recur within a family, but often display variable
 84 expressivity [2]. LVOTO defects putatively caused by *NOTCH1* variants were initially
 85 described in two kindreds with truncating variants [3], and subsequently in several
 86 other families [4-12]. In addition to CHDs, *NOTCH1* mutations have been associated
 87 with Adams-Oliver syndrome, and certain types of cancers [14,15].

88
 89 Predicted loss of function (pLOF) variants, e.g. frameshift, nonsense, and splice site
 90 variants, in *NOTCH1* have been reproducibly associated with LVOTO defects in
 91 multiple studies, and several missense variants have been reported in persons with
 92 LVOTO (Fig 1) [3-12]. Previous surveys of LVOTO in both simplex and multiplex
 93 families, observed pathogenic or likely pathogenic *NOTCH1* variants in 1-18% of
 94 families [5,8,11].

95
 96 Both the initial description of *NOTCH1* in LVOTO and subsequent reports include

affected members with CHDs other than LVOTO defects including ventricular septal defects and Tetralogy of Fallot (TOF) [3, 11-12]. Additionally, study design has varied among previous analyses rendering estimation of risk and comparisons between studies difficult. Accordingly, while it is clear that pLOF *NOTCH1* variants are associated with LVOTO defects, the role of missense variants and therefore the overall attributable risk of *NOTCH1* variants to LVOTO defects remains unclear.

Here, we describe the presence of pLOF and missense variants in *NOTCH1* in a cohort of 49 simplex cases with HLHS. In addition, we use a large population-based study to assess the risk for LVOTO related heart defects conferred by variants in *NOTCH1* to identify two rare intronic risk variants.

Results

Exome Sequencing Reveals Likely Pathogenic Variants and Variants of Unclear Significance

A total of 11 of the 49 probands (22%) had seven protein-altering *NOTCH1* variants, each with a MAF of < 0.05. Three pLOF variants met criteria for pathogenicity (Table 1 and Fig 3). A novel (i.e., absent from all databases) *de novo* truncating variant c.1077C>A (p.Cys359*) with a CADD score of 37 was found in a single HLHS proband. A truncating variant c.1650_1651insT (p.Tyr550*), with a CADD score of 35, was found in a proband with HLHS and CoA and her unaffected parent. p.Tyr550* had been reported previously in a family with Adams-Oliver syndrome (AOS) [20]. A novel splicing variant, c.431-1G>A, with a CADD score of 26 was found in a simplex family with HLHS. This variant was inherited from their father from whom a DNA sample was unavailable.

Table 1. Non-synonymous *NOTCH1* variants identified in 49 probands with HLHS

Diagnosis	Chr	Position	Ref	Alt	dbSNP	DNA change	Protein change	Effect	Allele frequency in gnomAD Finnish	CADD score	Inherited
HLHS	9	139413065	G	T	N/A	1077C>A	Cys359*	Stopgain SNV	0	38,0	No
HLHS, CoA	9	139410452	G	GT	N/A	1650_1651insA	Y550_T551*	Stopgain SNV	0	35,0	Yes
HLHS	9	139404414	C	T	N/A	c.2741-1G>A		Splicing	0	26,0	Yes
5 HLHS, 1 BAV*	9	139401233	C	T	rs61751543	3836G>A	Arg1279His	ns SNV	0,02097	16,2	Yes 2/ Not known 3
HLHS	9	139401216	C	T	N/A	3853G>A	Val1285Met	ns SNV	0	29,8	29,8
HLHS	9	139391338	C	T	rs61751489	6853G>A	Val2285Ile	ns SNV	0,00617	0.5	Not known
HLHS, BAV, CoA, HAA, ASD, VSD	9	139391013	T	C	N/A	7178A>G	Gln2393Arg	ns SNV	0	10,1	Not known

* 6 affected

Among the four remaining *NOTCH1* variants, a missense variant c.3836G>A

(p.Arg1279His) was found in 5 HLHS probands and in one person with BAV who was a half-sister of a proband. p.Arg1279His has been found in both persons with LVOTO and in controls in three previous studies [6,7,9]. Another missense variant, c.6853G>A (p.Val2285Ile), was found in one child with HLHS and his unaffected parent. A novel missense variant, c.7178A>G (p.Gln2393Arg), was found in a proband with HLHS, BAV, CoA, HAA, ASD, VSD. Finally, a rare missense variant c.3853G>A (p.Val1285Met), was found in a singleton proband with HLHS.

Rare intronic variants in *NOTCH1* are associated with risk for LVOTO in European and non-European populations

Given the uncertain of whether the four missense variants detected in the probands with HLHS were causal, we decided to test the association of common and rare coding and noncoding variants in *NOTCH1* with risk of LVOTO and related CHD phenotypes more broadly in UK Biobank, a large population-based study. We first developed a classification scheme to identify 396 cases with LVOTO in a highly specific manner. To determine the power for detecting associations with rare-variants, we performed simulations of the Firth's penalized regression. As BAV was included in our definition of LVOTO and may commonly remain undiagnosed in the population at a significant rate, our simulations included misspecification of cases as controls. Power was largely dependent on the minor allele frequency, with misspecification of cases playing a negligible role in power at all simulated rates of misspecification of cases (S1 Fig). For the combined hybrid-LVOTO phenotype (n=271) the power to detect a genetic association with even low-risk variants of OR 2 or greater was nearly 100% at a minor allele frequency of 0.001, and at a minor allele frequency of 0.0001 nearly 80% to detect variants conferring a risk of 12.9 or higher

(S1 Fig). These simulations provide evidence of adequate power to detect genetic associations for CHD phenotypes related to *NOTCH1* even in the presence of unrecognized cases within a large control population.

We identified 400 non-coding or coding (missense and synonymous) variants in *NOTCH1* and no pLOF variants (S1 Table) available for analysis imputed with high quality. Among these 400 variants, none of the coding variants met our pre-specified threshold for locus wide significance. Two of the four non-synonymous variants we observed Finnish cohort (Val2285Ile and Arg1279His) were present in the UK biobank cohort but were not significantly associated with CHD.

Associations the hybrid LVOTO phenotype with two rare intronic variants in *NOTCH1* (g.chr9:139427582C>T, Odds Ratio 16.9, p=3.12e-6 and g.chr9:139435649C>T, Odds Ratio 19.6, p = 2.44e-6) met the locus-wide threshold for significance (Fig 4). As these two intronic variants appear at similar frequencies within non-European populations in the gnomAD database of population level genomic variation, we repeated analysis limited to the 68,952 individuals of non-European and mixed ancestry within the UK Biobank. The association with risk for LVOTO identified was of the same direction and similar magnitude (g.chr9:139427582C>T, Odds Ratio 12.3, p=0.019 and g.chr9:139435649C>T, Odds Ratio 13.9, p = 0.014) (Fig 4 and Fig 5).

Discussion

We detected a likely pathogenic/pLOF mutation in *NOTCH1* in 6% of individuals with HLHS in a Finnish cohort [21]. These variants included a splicing variant and two truncating variants. These findings suggest that pLOF variants in *NOTCH1* may be sufficiently prevalent in LVOTO defects to warrant genetic testing. An additional 16%

of HLHS probands in this cohort had missense variants of unknown significance. Further study of missense *NOTCH1* variants in a large population-based study of LVOTO defects did not reveal any significant association between missense variants and risk for less severe LVOTO-related defects. In the population-based study, neither common nor rare missense variants in *NOTCH1* were significantly associated with LVOTO defects. Notably, no pLOF variants were identified in the population-based study cohort, suggesting that such variants are very rare in putatively healthy population controls.

Two rare intronic variants displayed strong association with risk for LVOTO defects in both European and non-European/mixed populations. These two variants appear to exist in similar frequencies in European (MAF=0.00074), Ashkenazi Jewish (MAF=0.0078), and African (MAF=0.0003) populations, and are separated by 8,068 base pairs and display strong linkage disequilibrium ($r^2 = 0.949$) suggesting the associations with LVOTO are not unique or independent. The two variants exist within the large intron between the second and third exons of *NOTCH1*, and are not located with sufficient proximity to exert a functional effect on canonical splicing of the transcripts for *NOTCH1* or nearby microRNAs (*MIR4673* and *MIR4674*) and additionally do not appear to be strongly conserved through evolution. Thus a direct effect of the two variants upon the protein sequence or structure of *NOTCH1* is not clear and will require an experimental approach to determine function which may be related to transcription or epigenetic regulation.

The absence of a significant association of missense variants in *NOTCH1* with LVOTO-related phenotypes in UK Biobank must be interpreted with attention to the characteristics of the study population. Long-term survival of patients with HLHS was

achieved by surgical innovations during 1980's, and thus there were no patients with HLHS within the UK Biobank cohort, which consists of middle-aged to elderly individuals from the general population. The small fraction of individuals classified with LVOTO is lower than previous population estimates of BAV (the most common type of LVOTO) suggesting some ascertainment errors due to the use of phenotyping from medical records, perhaps in a combination with a healthy cohort effect (the individuals in UK Biobank being healthier than the general population). Moreover, as pathogenic *NOTCH1* mutations have been found more frequently in pediatric study cohorts than in adult cohorts, it has been speculated that *NOTCH1* mutations are more often found in severe disease [11]. Cardiac MRI data are currently available for a small fraction of individuals within the UKBiobank. Of the LVOTO cases classified by the specification schema, two individuals identified had available MRI imaging, and both were positively identified as having bicuspid aortic valve. Our algorithmic approach to classification of individuals with CHD relying upon clinical and self-reported data requires additional validation, but the overall approach may offer insight into rare alleles conferring risk for disease that has been obscured by the underlying genetic architecture of complex diseases in diverse human populations [22].

Two of our 49 probands had novel truncating variants, and truncating variants in *NOTCH1* have been reproducibly associated with LVOTO defects. A total of 14 of the 138,632 gnomAD subjects have truncating *NOTCH1* variants and the probability of loss of function variant intolerance (pLI) is estimated to be 1.0. Previously both *de novo* [10] and familial [11] splice site variants have been reported in LVOTO subjects. The splice site variant 431-1G>A found in an HLHS proband in this study was also found in the asymptomatic father indicating reduced penetrance, which is in

accordance with a previous study where familial splicing variants had 87% penetrance [11]. According to the Human Splicing Finder, the 431-1G>A variant alters the WT acceptor site and is likely to affect splicing [25]. Only 5 of 138,632 individuals included in gnomAD have splice site variants in *NOTCH1*, indicating these are poorly tolerated variants.

The truncating p.Tyr550* variant found in one of the HLHS probands studied herein has been previously reported in a kindred with four affected members with AOS with variable expression of congenital limb defects and scalp cutis aplasia [20]. Of these four AO individuals, one had undergone cardiac evaluation by echocardiogram showing AS and aortic regurgitation. Functional analysis associated the variant with reduced expression of *NOTCH1*, *HEY1* and *HES1* in peripheral blood as measured by RT-PCR indicating that the truncated protein is likely to be subject to nonsense-mediated decay reducing the downstream *NOTCH1* signaling. Notably, two family members with this variant did not have AOS; however, one of them had an unexplained heart murmur, and the other had aortic regurgitation, and a family member with unknown genetic variant status died of an unspecified CHD.

Based on our analyses in the UK Biobank, which failed to detect a significant association of missense variants in *NOTCH1* with LVOTO-related phenotypes, we think the four non-synonymous variants are not able to cause disease in isolation. However, the inheritance pattern of CHD is in many cases complex, and the contribution of these variants to disease together with other predisposing environmental or genetic factors cannot be determined. The Arg1279His variant (rs61751543) is particularly interesting, as it has been seen more frequently in cases vs. controls in three previous LVOTO cohorts[6,7,9]. In this study it is seen in 5/49

(10%) HLHS probands compared to 2% of the Finnish gnomAD population. The variant has a CADD score of 16.23, which could be interpreted to suggest potential pathogenicity *in silico*. Notably, the Finnish gnomAD population has not been phenotyped for CHD, and likely contains some sporadic individuals with undiagnosed BAV, which is relatively common. However, recent analyses incorporating variant penetrance and incomplete ascertainment of control populations [26] suggest that a conservative view must be taken when assigning disease risk for individual variants. Additionally, in functional analysis the Arg1279His variant does not diminish *JAG1* induced *NOTCH1* signaling [6]. Functional studies on the role of low-frequency variants overrepresented in CHD in patient-derived induced pluripotent stem cells would be fruitful in assessing their pathogenic potential.

The discovery of the same truncating variant in a family with HLHS and a family with AOS with minor or no detectable cardiac phenotype is illustrative of variable phenotypic expressivity. Different mutations in the same gene causing different phenotypes in different families may be due to the presence of modifying mutations within a network of interacting proteins [27], stochastic differences in transcriptional dynamics or cardiovascular development, poorly characterized aspects of epigenetic inheritance, or environmental factors. Given that epistatic effects between genetic variants are difficult to detect even in large genetic studies [28], discovery of modifying factors (genetic, environmental, epigenetic, or otherwise) may depend on hypothesis-driven experimental approaches [29].

In conclusion, in our study of 49 HLHS individuals, three (6%) had loss of function variants, which are likely causative for the congenital heart defects. In addition, five

affected individuals (10%) and one affected relative displayed a low frequency variant p.Arg1279His present in 2% of the general population which does not appear to be associated with risk for disease in a large-scale association study of less severe phenotypes. Two rare intronic variants displayed strong association with risk for LVOTO defects. However, due to their deep intronic location, the direct functional effect of the two variants upon *NOTCH1* is not clear. Our finding of pathogenic *NOTCH1* variants in 6% of the study subjects is similar in prevalence to single genes causing Long QT syndrome and hypertrophic cardiomyopathy, cardiac conditions for which genetic testing is routine. Thus our data are supportive of the use of clinical testing for *NOTCH1* variant screening patients with HLHS and other LVOTO.

Rare, highly penetrant LOF variants clearly increase risk for nonsyndromic CHD[30,31] in a small percentage of the general population while the role of missense variants remains unclear. Genetic risk factors that explain the bulk of syndromic and non-syndromic CHD remain to be discovered. Moreover, the role of environmental modifiers and interactions among loci remain largely unexplored. Access to large cohorts of robustly phenotyped families with CHD and the availability of comparative genomic data sets from large reference populations will enable both careful assessment of the pathogenicity of rare variants and facilitate identification of novel variants / genes associated with CHD. Functional studies of the pathogenic potential of such variants in patient-derived induced pluripotent stem cells may confirm the pathogenicity of these variants and may serve to elucidate mechanisms behind reduced penetrance. For genes where causality for cardiac malformations is well established, our findings may suggest an opportunity to quantify risk conferred by inherited alleles to increase the known fraction of genetic attributable risk for CHD.

Methods

Exome Sequencing in Finnish Probands and Relatives

We recruited a cohort of 49 patients with HLHS from Helsinki University Children's Hospital. Exome sequencing was performed by the University of Washington Center for Mendelian Genomics Seattle, USA, on DNA samples collected from 37 probands, 7 trios (5 with unaffected or unknown parental phenotypes, and 2 with one affected parent), and 5 probands with a family history of LVOTO defects. In these latter cases, we sequenced the parents, siblings and other affected family members (Fig 2a-c). All persons sequenced were of self-reported Finnish ancestry.

In brief, library capture was performed with Roche/Nimblegen SeqCap EZ v2.0, with 75-base pair paired-end sequencing on the HiSeq2500/4000 instrument (RTA 1.18.34/RTA 2.5.2). BAM files were aligned to a human reference (hg19hs37d5) using BWA-MEM (Burrows-Wheeler Aligner; v0.7.10) [32]. Read-pairs not mapping within ± 2 standard deviations of the average library size ($\sim 150 \pm 15$ bp for exomes) were removed. RTG-core version 3.3.2 was applied to the raw exome sequence data for mapping, pedigree-aware variant calling, and genotype filtration (Real Time Genomics Inc., Hamilton, New Zealand) [33].

We analyzed all non-synonymous *NOTCH1* variants found with an allele frequency of <0.05 in the Genome Aggregation Database (gnomAD) [34]. In addition, we checked the occurrence and frequency of the candidate variants in the Sequencing Initiative Suomi (SISu) [35] database. Annotation was performed with the internally developed STANNOVAR tool [36]. Combined Annotation Dependent Depletion (CADD) scores were used to estimate the pathogenicity of the candidate variants.

CADD is a tool for scoring the deleteriousness of single nucleotide variants as well as insertion/deletions variants in the human genome. The CADD score integrates multiple annotations into one metric by contrasting variants that survived natural selection with simulated mutations [37]. Likely pathogenic variants were confirmed with Sanger sequencing of PCR amplicons in all available family members. The following PCR primers were used: NOTCH1 p.Tyr550Ter: Forward-GCACACTCGTTGATGTCCTC, Reverse-AGAACTGTCTCTCCTCCCCT; NOTCH1 c.431-1G>A: Forward-TACTCAGGATTGGGGCTGAG, Reverse-GAAGGGCCATAGTGCTGTTG; NOTCH1 p.Cys359Ter: Forward-GTTGTAAAACGACGGCCAGTGTGAGGTCACACAGCTCAGG, Reverse-TCACACAGGAAACAGCTATGAGTACCGAGGATGTGGACGAG.

The guidelines of the Declaration of Helsinki were followed and the study was approved by the Ethics Board of Helsinki and Uusimaa Hospital District. Written informed consent was obtained from each participant over 6 years of age, and from both parents of each minor participant.

Population Studies in the UK Biobank

Classification of Left Ventricular Outflow Tract Disease from Biobank Data. A classification algorithm (S2 Fig) was developed for defining case and control subjects using diagnostic codes from the International Classification of Diseases versions 9 and 10, the OPCS Classification of Interventions and Procedures version 4, and from self-reported medical history data collected in a questionnaire and codified by a trained nurse for the UK Biobank study (all codes listed in S3 Table). The LVOTO phenotype was defined as comprising the following individual phenotypes of congenital etiology: aortic stenosis, subaortic stenosis, aortic

insufficiency, aortic coarctation, aortic atresia, congenital aneurysm of the aorta, and hypoplastic left heart syndrome. Since an undiagnosed bicuspid aortic valve may manifest with outflow obstruction (i.e. aortic stenosis and/or insufficiency) later in life, the classification algorithm was designed to identify patients with bicuspid aortic valves who otherwise were not codified as having a congenital heart defect, a process not previously defined in the literature. Patients with aortic valve disease with unspecified etiology or who had had an aortic valve replacement were excluded from cases and reclassified as controls if they met criteria for non-congenital etiologies of valve disease (i.e. rheumatic heart disease, endocarditis, etc.) (S3 Table). Furthermore, of the remaining cases, if the age at diagnosis was >45 for aortic valve disease and age at surgery was >50 for valve replacement, then the patient was excluded to reduce the chance of false positives due to age-related degenerative aortic valve disease. False positive rates were predicted using data on the frequency of bicuspid aortic valves by decade of life published in 2011 by Roberts and Ko [38]. Lastly, control subjects meeting criteria for diagnoses that are associated with syndromic or sporadic congenital heart disease (i.e. endocarditis, thoracic aortic aneurysm, aortic root dilation) but otherwise unable to meet inclusion criteria were excluded to minimize the chance of false negatives in the control population (S3 Table).

Association Testing for *NOTCH1* Variants. We performed a primary genetic association study for LVOTO and related phenotypes in 271 cases and 333,571 controls of European ancestry included in the recent release of imputed genetic data from the UK Biobank [39,40]. From the dataset of imputed variants, we analyzed 400 common and rare variants in *NOTCH1*. Summary statistics from the association tests of European ancestry participants can be found in S4 Table.

Statistical testing was performed by standard methodology using PLINK version 2.0 using the hybrid logistic regression with Firth's penalized regression fallback for non-converging models with PLINK's *--glm firth-fallback* option) [41,42]. and included 10 principal components related to ancestry as continuous covariates and two binary covariates related to genotyping batch. From the imputed dataset, we included 400 exonic and intronic variants with 30 or more alleles in the population that had missing rates of 5% or lower and high quality imputation (95% or greater individuals for which the maximum genotype probability was greater than a threshold of 0.9), and which also displayed an empirical-theoretical variance ratio (MaCH's r^2) >0.8. For analysis of any single variant, individuals with missing calls were excluded. Primary testing was performed in 271 cases and 333,571 controls of white British origin. Confirmatory testing was performed in 51 cases and 68,952 controls of non-European or mixed ancestry.

We performed a single analysis of the LVOTO hybrid, and estimates of risk ratios and confidence intervals for individual variants were obtained including the same covariates, as mentioned above. Significance thresholds were predetermined; we report a locus-wide 0.000125 (0.05 / 400 analyzed variants in *NOTCH1*) significance threshold.

Power calculations were performed for unbalanced case control study design employing the *logistf* package implementation of the Firth's penalized logistic regression in the R language for statistical computing [42]. Firth's regression implementation in the *logistf* package is used by PLINK 2 for the association tests when conventional models fail to converge. Simulations were conducted in 1000 replicates holding constant a variant with a minor allele frequency of 0.1, 0.05, 0.01,

0.001, or 0.0001 and a control population size of 333,571 individuals, with variation of the genotype relative risk (GRR) at 2, 4, 8, 16, and 32. For simplicity the simulations employed an additive model of risk, for which the $GRR = f_1 / f_0$ where f_0 and f_1 represent the likelihood of being affected with LVOTO for individuals with 0 or 1 risk alleles respectively. Additionally, as our classification schema for cases was weighted towards specificity (described above) and the high likelihood of misspecification of undiagnosed BAV within the control population, we simulated mis-specification of controls at a rate of 0.01%, 0.1%, and 1%. Estimation of power for specific risk and allele frequencies was calculated using local polynomial regression from the simulated datasets.

Acknowledgements

Sequencing was provided by the University of Washington Center for Mendelian Genomics (UW-CMG) and was funded by the National Human Genome Research Institute and the National Heart, Lung and Blood Institute grant HG006493 to Drs. Deborah Nickerson, Michael Bamshad, and Suzanne Leal.

REFERENCES

1. Reller MD, Strickland MJ, Riehle-Colarusso T, Mahle WT, Correa A. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr. 2008;153(6):807-813.
2. Øyen N, Poulsen G, Boyd HA, Wohlfahrt J, Jensen PK, Melbye M. Recurrence of congenital heart defects in families. Circulation. 2009;120(4):295-301.
3. Garg V, Muth AN, Ransom JF, Schluterman MK, Barnes R, King IN, et al. Mutations in NOTCH1 cause aortic valve disease. Nature. 2005;437:270-4.
4. Mohamed SA, Aherrahrou Z, Liptau H, Erasmi AW, Hagemann C, Wrobel S, et al. Novel missense mutations (p.T596M and p.P1797H) in NOTCH1 in patients with bicuspid aortic valve. Biochem Biophys Res Commun. 2006;345(4):1460-5.
5. McKellar SH, Tester DJ, Yagubyan M, Majumdar R, Ackerman MJ, Sundt TM. Novel NOTCH1 mutations in patients with bicuspid aortic valve disease and thoracic aortic aneurysms. J Thorac Cardiovasc Surg. 2007;134:290–296.
6. McBride KL, Riley MF, Zender GA, Fitzgerald-Butt SM, Towbin JA, Belmont JW, et.al. NOTCH1 mutations in individuals with left ventricular outflow tract malformations reduce ligand-induced signaling. Hum Mol Genet. 2008;17:2886–2893.
7. Iascone M, Ciccone R, Galletti L, Marchetti D, Seddio F, Lincetto AR, et al. Identification of *de novo* mutations and rare variants in hypoplastic left heart syndrome. Clin Genet. 2012;81:542–554.
8. Foffa I, Ait Ali L, Panesi P, Mariani M, Festa P, Botto N, et al. Sequencing of NOTCH1, GATA5, TGFB1 and TGFB2 genes in familial cases of bicuspid

432 aortic valve. BMC Med Genet. 2013;Apr11;14:44

433 9. Freylikhman O, Tatarinova T, Smolina N, Zhuk S, Klyushina A, Kiselev A, et

434 al. Variants in the NOTCH1 gene in patients with aortic coarctation. Congenit

435 Heart Dis. 2014;Sep-Oct;9(5):391-6.

436 10. Theis JL, Hrstka S, Evans JM, O'Byrne MM, de Andrade M, O'Leary PW, et al.

437 Compound heterozygous NOTCH1 mutations underlie impaired cardiogenesis

438 in a patient with hypoplastic left heart syndrome. Hum Genet. 2015;134:1003–

439 1011

440 11. Kerstjens-Frederikse WS, van de Laar I, Vos YJ. Cardiovascular

441 malformations caused by NOTCH1 mutations do not keep left: data on 428

442 probands with left-sided CHD and their families. Genet Med. 2016; 18(9):914–

443 23.

444 12. Preuss C, Capredon M, Wunnemann F, Chetaille P, Prince A, Godard B, et al.

445 Family Based Whole Exome Sequencing Reveals the Multifaceted Role of

446 Notch Signaling in Congenital Heart Disease. PLoS Genet. 2016;12(10):

447 e1006335.

448 13. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control

449 and signal integration in development. Science. 1999;284: 770–6

450 14. Stittrich AB, Lehman A, Bodian DL, Ashworth J, Zong Z, Li H et al. Mutations

451 in NOTCH1 cause Adams-Oliver syndrome. Am J Hum

452 Genet. 2014;95(3):275-84.

453 15. Radtke F. and Raj K. The role of Notch in tumorigenesis: oncogene or tumour

454 suppressor? Nat Rev Cancer. 2003;Sep3:756–767. □ □

455 16. Yang B, Zhou W, Jiao J, Nielsen JB, Mathis MR, Heydarpour M, et al. Protein-

456 altering and regulatory genetic variants near GATA4 implicated in bicuspid

457 aortic valve. *Nat Commun.* 2017;May25:8:15481.

458 17. Tan HL, Glen E, Töpf A, Hall D, O'Sullivan JJ, Sneddon L, et al.

459 Nonsynonymous variants in the SMAD6 gene predispose to congenital

460 cardiovascular malformation. *Hum Mutat.* 2012;33(4):720-7.

461 18. Shi LM, Tao JW, Qiu XB, Wang J, Yuan F, Xu Let al. GATA5 loss-of-function

462 mutations associated with congenital bicuspid aortic valve. *Int J Mol Med.*

463 2014; 33(5):1219-26.

464 19. Qu XK, Qiu XB, Yuan F, Wang J, Zhao CM, Liu XY et al. A novel NKX2.5

465 loss-of-function mutation associated with congenital bicuspid aortic valve. *Am*

466 *J Cardiol.* 2014;114(12):1891-5.

467 20. Southgate L, Sukalo M, Karountzos AS, Taylor EJ, Collinson CS, Ruddy D, et

468 al. Haploinsufficiency of the NOTCH1 Receptor as a Cause of Adams-Oliver

469 Syndrome With Variable Cardiac Anomalies. *Circ Cardiovasc Genet.*

470 2015;Aug;8(4):572-81

471 21. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J et al. Standards

472 and Guidelines for the Interpretation of Sequence Variants: A Joint

473 Consensus Recommendation of the American College of Medical Genetics

474 and Genomics and the Association for Molecular Pathology. *Genet Med.*

475 2015;17(5):405-424.

476 22. Uricchio LH, Zaitlen NA, Ye CJ, Witte JS, Hernandez RD. Selection and

477 explosive growth alter genetic architecture and hamper the detection of causal

478 rare variants. *Genome Res.* 2016;26(7):863-73

479 23. Bonachea EM, Chang SW, Zender G, LaHaye S, Fitzgerald-Butt S, McBride

480 KL, et al. Rare GATA5 sequence variants identified in individuals with bicuspid

481 aortic valve, *Pediatr Res.* 2014;Aug;76(2):211-6.

24. Padang R, Bagnall RD, Richmond DR, Bannon PG, Semsarian C. Rare non-synonymous variations in the transcriptional activation domains of GATA5 in bicuspid aortic valve disease. *J Mol Cell Cardiol.* 2012;Aug;53(2):277-81.
25. Desmet FO, Hamroun D, Lalande M, Collod-Bérout G, Claustres M, Bérout C. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. *Nucleic Acids Res.* 2009;May;37(9):e67.
26. International Multiple Sclerosis Genetics Consortium. NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk. *Neuron.* 2016;Oct19;92(2):333-335
27. Sahni N, Yi S, Taipale M, Fuxman Bass JI, Coulombe-Huntington J, Yang F, et al. Widespread macromolecular interaction perturbations in human genetic disorders. *Cell.* 2015;Apr23;161(3):647-60.
28. Wei W-H, Hemani G, and Haley S. Detecting epistasis in human complex traits. *Nat Rev Genet.* 2014;15(11):722-733.
29. Ang YS, Rivas RN, Ribeiro AJ, Srivas R, Rivera J, Stone NR et al. Disease Model of GATA4 Mutation Reveals Transcription Factor Cooperativity in Human Cardiogenesis. *Cell.* 2016;Dec15;167(7):1734-1749.e22.
30. Sifrim A, Hitz MP, Wilsdon A, Breckpot J, Turki SH, Thienpont B et al. Distinct genetic architectures for syndromic and nonsyndromic congenital heart defects identified by exome sequencing. *Nat Genet.* 2016;Sep;48(9):1060-5
31. Blue GM, Kirk EP, Giannoulatou E, Dunwoodie SL, Ho JW, Hilton DC, et al. Targeted next-generation sequencing identifies pathogenic variants in familial congenital heart disease. *J Am Coll Cardiol.* 2014;Dec16;64(23):2498-506.
32. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics.* 2009;Jul15;25(14):1754-60.
33. Reumers J, De Rijk P, Zhao H, Liekens A, Smeets D, Cleary J, et

507 al. Optimized filtering reduces the error rate in detecting genomic variants by
508 short-read sequencing. *Nat Biotechnol.* 2011;30:61–68.

509 34. Exome Aggregation Consortium, Lek M, Karczewski KJ, Minikel EV, Samocha
510 KE, Banks E, et al. Analysis of protein-coding genetic variation in 60,706
511 humans. *bioRxiv* 030338; doi: <https://doi.org/10.1101/030338>.

512 35. Sequencing Initiative Suomi project (SISu), Institute for Molecular Medicine
513 Finland (FIMM), University of Helsinki, Finland. <http://sisuproject.fi>. (SISu v4.1,
514 accessed May 15th 2017).

515 36. Dewey FE, Grove ME, Priest JR, Waggott D, Batra P, Miller CL, et al.
516 Sequence to Medical Phenotypes: A Framework for Interpretation of Human
517 Whole Genome DNA Sequence Data. *PLoS Genet.* 2015;Oct
518 8;11(10):e1005496.

519 37. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure JA. A
520 general framework for estimating the relative pathogenicity of human genetic
521 variants. *Nat Genet.* 2014;46(3):310-5.

522 38. Roberts WC, Ko JM. Frequency by Decades of Unicuspid, Bicuspid, and
523 Tricuspid Aortic Valves in Adults Having Isolated Aortic Valve Replacement
524 for Aortic Stenosis, With or Without Associated Aortic Regurgitation.
525 *Circulation.* 2005;111(7):920-925.

526 39. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK
527 biobank: an open access resource for identifying the causes of a wide range
528 of complex diseases of middle and old age. *PLoS Med.*
529 2015;Mar31;12(3):e1001779.

530 40. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. Genome-
531 wide genetic data on~ 500,000 UK Biobank participants. *bioRxiv*.

532   2017:166298 doi: <https://doi.org/10.1101/166298>.

533   41. Chang CC, Chow CC, Tellier LCAM, Vattikuti S, Purcell SM, Lee JJ. Second-

534   generation PLINK: rising to the challenge of larger and richer datasets.

535   GigaScience, 2015;4:7.

536   42. Heinze G, Ploner M, Beyea J. Confidence intervals after multiple imputation:

537   combining profile likelihood information from logistic regressions. Stat Med.

538   2013;Dec20;32(29):5062-76.

539

540 Figure captions

541

542 Figure 1. Previously reported non- synonymous and pLOF *NOTCH1* mutations in

543 LVOTO subjects^{41,42}.

544 Figure 2. Pedigrees of 5 trios with unaffected (a-c), unknown (d, e), and possibly

545 affected (f, g) parental phenotypes, and pedigrees of 6 families with more than one

546 affected member (h-m).

547 Figure 3. Non- synonymous and pLOF mutations in *NOTCH1* in the study population

548 presented in Mutation Mapper as a lollipop plot^{41,42}.

549 Figure 4. Region plot for the association of *NOTCH1* variants with LVOTO.

550 Figure 5. Effect sizes of the associated *NOTCH1* variants in European and non-

551 European and mixed populations.

NOTCH1

? = Unknown phenotype

NOTCH1

Plotted SNPs

9:139427582 C>T

9:139435649 C>T